

Special Issue

Cystic Fibrosis: Genetics, Pathophysiology and Novel Therapeutic Approaches

Message from the Guest Editors

Cystic fibrosis (CF) is a life-threatening autosomal recessive disorder due to mutations in the CF Transmembrane Conductance Regulator (*CFTR*) gene that cause morbidity and mortality mainly by inducing lung disease. This Special Issue is devoted to appraising the most recent developments in CF research and its clinical facets, focusing on the fields of genetics, theranostics, immunology, infections, inflammation, and novel therapeutic approaches. In the coronavirus 2019 (COVID-19) era, the natural history of CF pathophysiology is changing, thereby this Special Issue will be insightful in discussing how the present pandemic infection could determine other clinical features in CF patients. Finally, basic and applied research have sought and identified etiological treatments for CF, highlighted by the clinical use of modulators (potentiators, correctors) of the mutated *CFTR* protein. Novel genetic and stem cell-based treatments as potential therapeutic approaches to cure CF are at the forefront of CF research and will be also covered in this Special Issue.

Guest Editors

Prof. Dr. Massimo Conese

Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy

Dr. Onofrio Laselva

Laboratory of Experimental and Regenerative Medicine, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy

Deadline for manuscript submissions

closed (30 June 2022)



Journal of Respiration

an Open Access Journal
by MDPI



mdpi.com/si/73401

Journal of Respiration
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jor@mdpi.com

mdpi.com/journal/

[jor](https://jor.mdpi.com)





Journal of Respiration

an Open Access Journal
by MDPI



mdpi.com/journal/

[jor](https://jor.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Over the last decade, the amount of information pertaining to thoracic structures has been unprecedented. The thorax is unique in terms of the different structures that involve the respiratory system—lungs, pleura, upper and lower respiratory tract—all located in the mediastinum that by itself represents a different compartment with its own wealth of conditions, and that also includes the Thymic gland. Therefore, we believe that the availability of a new open access journal, *JoR*, dedicated to highlighting and disseminating information related to the respiratory system is not only timely but is also absolutely necessary. As we can see, the information related to the respiratory systems is vast and there could not be anything more and better than to have a journal that is dedicated to the promotion, dissemination, and efficient publication of timely articles on the respiratory system including all its structures.

Editor-in-Chief

Prof. Dr. Cesar A. Moran

Department of Pathology, University of Texas MD Anderson Cancer
Center, Houston, TX, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 52.3 days after submission; acceptance to publication is undertaken in 4.9 days (median values for papers published in this journal in the second half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.